EXCLUSIVE ONLINE CONTENT
Amicus Therapeutics, Inc. has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and capacity…
Arcturus Therapeutics Holdings Inc. recently announced the US FDA has granted Orphan Drug Designation for the company’s lead product candidate………
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit recently announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to……..
As the Spring heat made the light dance around the skin of the largest convention center in America, winners emerged from ASCO last month. One of the most significant announcements (from Iovance Biotherapeutics Inc.) were two first-in-man studies of adoptive T cell therapy (ACT) in patients with melanoma and cervical cancer which had failed to respond to other treatments.
Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies
The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.